TTP 22

TTP 22

Catalog Number:
L002368914APE
Mfr. No.:
APE-A3894
Price:
$281
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          IC50= 0.1 μM; Ki= 40 nM
          TTP 22 is a high affinity, ATP-competitive casein kinase 2 (CK2) inhibitor.
          Casein kinase 2 (CK2) noticeably stands out against a background of the kinase family due to its constitutive catalytic activity with the ability to phosphorylate more than 300 physiological substrates. These features make CK2 appear greatly diverse points of cell signaling pathways and be involved in processes leading to the development of various disorders, especially cancer. Thus, currently CK2 is regarded as druggable protein kinase target and can be used for the development of antitumor, anti-inflammatory and antiviral drugs.
          In vitro: Kinetic studies of TTP 22 showed that activity of (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids moiety was a result of its competition with ATP molecule for the binding site. Inhibition constant (Ki) for TTP 22 was 40 nM. Initial in vitro tests of TTP 22 and it analog on four serine/threonine (ASK1, JNK3, Aurora A and Rock 1) and three tyrosine protein kinases (FGFR1, Met and Tie2) revealed their remarkable specificity towards CK2 [1].
          In vivo: So far, no animal in vivo study has been conducted for TTP 22.
          Clinical trial: N/A

      • Properties
        • Alternative Name
          TTP22;TTP-22; 3-[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]sulfanylpropanoic acid
          CAS Number
          329907-28-0
          Molecular Formula
          C16H14N2O2S2
          Molecular Weight
          330.42
          Appearance
          A solid
          Purity
          98.33%
          Solubility
          insoluble in H2O; ≥16.5 mg/mL in DMSO; ≥7.85 mg/mL in EtOH with gentle warming and ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Zhao Z, Wang L, et al."Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia." Genes Dev. 2019 Jan 1;33(1-2):61-74. PMID:30573454

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.